GANN THERAPEUTICS NASDAQ: GANX

TRANSFORMING THE TREATMENT OF PARKINSON'S DISEASE

Corporate Presentation *August 2024*

Forward-Looking Statements

Forward-Looking Statements

Certain statements set forth in this presentation are forward-looking and reflect the Company's plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance (collectively referred to herein as "forward-looking statements"). Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and are often characterized by the use of words such as "believe," "can," "could," "potential," "plan," "predict," "goals," "seek," "should," "may," "may have," "would," "estimate," "continue," "anticipate," "intend," "expect" or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause our actual results, performance or achievements or industry results to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements.

These include, but are not limited to, statements about the Company's ability to develop, obtain regulatory approval for and commercialize its product candidates; the timing of future IND submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates; the Company's success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials; the outbreak of the novel strain of coronavirus disease, COVD-19, which could adversely impact our business, including our preclinical studies and any future clinical trials; the potential benefits of our product candidates; the Company's ability to obtain regulatory approval to commercialize our existing or any future product candidates; the Company's ability to identify patients with the diseases treated by our product candidates, and to enroll patients in clinical trials; the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Magellan platform; the Company's expectations regarding collaborations and other agreements with third parties and their potential benefits; the Company's ability to obtain, maintain and protect our intellectual property; the Company's reliance upon intellectual property licensed from third parties, including the license to use ourMagellan platform; the Company's competitors or industry; the impact of laws and regulations; the Company's expectations regarding the time during which it will be an emerging growth company under the JOBS Act; and other factors and assumptions described in the Company's public filings.

These statements are based on the Company's historical performance and on its current plans, estimates and projections in light of information currently available to the Company, and therefore, you should not place undue reliance on them. The inclusion of forward-looking information should not be regarded as a representation by the Company or any other person that the future plans, estimates or expectations contemplated by us will be achieved. Forward-looking statements made in this presentation speak only as of the date of this presentation, and the Company undertakes no obligation to update them in light of new information or future events, except as required by law.

You should carefully consider the above factors, as well as the factors discussed elsewhere in this presentation and our public filings, before deciding to invest in our common stock. The factors identified above should not be construed as an exhaustive list of factors that could affect the Company's future results, and should be read in conjunction with the other cautionary statements that are included in this presentation and our public filings. New risks and uncertainties arise from time to time, and it is impossible for the Company to predict those events or how they may affect the Company. If any of these trends, risks or uncertainties actually occurs or continues, the Company's business, revenue and financial results could be harmed, the trading prices of its securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Trademarks, Service Marks, and Trade Names

This presentation includes our trademarks, and trade names, which are protected under applicable intellectual property laws. This presentation also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in this presentation are listed without the TM, SM, ©, and ® symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors, if any, to these trademarks, service marks, trade names, and copyrights.

Industry Information

Market data and industry information used throughout this presentation are based on management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon management's review of independent industry surveys and publications and other publicly available information prepared by a number of third party sources. All of the market data and industry information used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although we believe that these sources are reliable, we cannot guarantee the accuracy or completeness of this information, and we have not independently verified this information. While we believe the estimated market position, market opportunity and market size information included in this presentation are generally reliable, such information, which is derived in part from management's estimates and beliefs, is inherently uncertain and imprecise. No representations or warranties are made by the Company or any of its affiliates as to the accuracy of any such statements or projections. Projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties.



GANX Corporate Highlights



Lead Product GT-02287 Advancing into GBA1 Parkinson's Disease Patients


- Restoring motor function and improving cognition potential to slow or stop PD progression
- Safety and tolerability has been established in healthy volunteers with further PK analysis forthcoming
- Translation of GT-02287's impact on important biomarkers of PD from animal models to PD patients is the focus of clinical development over the next 12 months

FOR PARKINSON'S RESEARCH



GANX Early Support for GT-02287

- Michael J. Fox Foundation for Parkinson's Research
- The Silverstein Foundation for Parkinson's with GBA
- Innosuisse (Swiss Innovation Agency)



Our Proprietary Magellan[™] AI Platform Discovers Novel First-in-Class Therapeutics

- Capable of efficiently screening library compounds in the trillions
- Select or provide constructs of molecules that can potentially target previously undruggable proteins
- We estimate our AI approach can generate leads for optimization in a little as three months



Experienced Leadership Team and Board

- 42 drug approvals
- \$45B+ in strategic transactions



he Silverstein

for Parkinson's with GBA

Foundation

chweizerische Eidgenossenschaft

Innosuisse – Swiss Innovation Agency

Confédération suisse

Confederaziun svizra

Swiss Confederation

Confederazione Svizzera

Experienced Leadership


EXTENSIVE BIOTECH AND PHARMA EXPERIENCE (>\$15B TRANSACTIONS)





Strong Board of Directors

(>\$30B IN TRANSACTIONS)





Novel Pipeline Generated from Magellar™ Platform

THERAPEUTIC AREA	INDICATION	TARGET	DISCOVERY	RESEARCH	PRECLINICAL	PHASE 1
Nourodogonorativo Disassos	Parkinson's Disease	GCase				
Neurodegenerative Diseases	Dementia with Lewy Bodies Alzheimer's Disease	GCase				
Lysosomal Storage Disorders	Gaucher Disease	GCase				
	GM1 Gangliosidosis	GLB1				
	Krabbe Disease	GALC				
Metabolic Diseases	Alpha1-Antitrypsin Deficiency	AAT				
Oncology	Solid Tumors	UNDISCLOSED				
	Solid Tumors	UNDISCLOSED				






Lead Clinical Program

GT-02287 GBA1 Parkinson's Disease


GBA-Parkinson's – A Genetically Defined Subpopulation of Parkinson's Disease






"Parkinson's Disease: Challenges, Progress, and Promise." National Institute of Neurological Disorders and Stroke, U.S. Department of Health and Human Services, 30 Sept. 2015 Smith, Laura, and Anthony H V Schapira. "GBA Variants and Parkins on Disease: Mechanisms and Treatments." Cells vol. 11,81261.8 Apr. 2022


Dysfunctional GCase Triggers Disease Cascade Affecting Multiple Organelle Functions and Leading to Neurodegeneration








Treatment with GT-02287 restores GCase Function, which improves Disease Cascade and Neuronal Survival



Confirmatory Data Generated with GT-02287








Animal PoC Studies – GT-02287 Improves Effects of GCase Dysfunction

CBE PD Model

- CBE is an inhibitor of the GCase enzyme
- Administration of CBE models the effects of dysfunctional GCase seen in GBA-Parkinson's








Results*


GT-02287 shows effects on neuronal health

- Depleted toxic substrate α -synuclein
- Reduced neuroinflammation (Iba-1)
- Increased neuron survival (NfL)

GT-02287 shows effects on motor function

 Increased fine motor skills and coordination (wire hang and beam walk)





CBE (100 mg/kg)
 +GT-02287 (30mg/kg)
 +GT-02287 (60mg/kg)
 +GT-02287 (90mg/kg)
 +GT-02287 (120mg/kg)

Vehicle Controls

Design: 8-10 weeks of age male C57BL/6 mice received daily CBE i.p. injections and oral q.d. drug treatment for 14 days. Wire hang test and beam walk test are performed at day 12. Sacrifice on day 14.


Data is shown as Mean ± S.E.M. One-way ANOVA followed by Dunnett's Multiple Comparison Test.****P < 0.0001.



*Additional data shows positive effects on GluCer(Cortex), Tyrosine Hydroxylase(SN), Striatal Dopamine, and NeuN (Cortex).

GT-02287 improves activities of daily living and cognitive performance in animal model of GBA1 Parkinson's disease

- Nest building is a noninvasive test to study activities of daily living and cognitive performance in rodent models
- Reduction in plasma levels of NfL, aggregated alpha-synuclein, GFAP, and Iba-1



GT-02287 improves nestbuilding performance

GT-02287 improves motor performance



GT-02287 has Best-in-Class Profile for GBA1-Parkinson's Disease of known GCasetargeting candidates

	Effect on Disease Cascade	GANN THERAPEUTICS GT-02287	
	Increases Lysosomal GCase Activity	✓	
	Reduces ER Stress	✓	
GCase	Reduces Toxic Lipid Substrates	✓	
Mechanism	Reduces Aggregated α-Synuclein	✓	
of Action	Improves Lysosomal Function	✓	
	Improves Mitochondrial Function	✓	
	Reduces Neuroinflammation	✓	
	Provides Neuroprotection	✓	
Disease-Modifying	Increases Dopamine Levels	✓	
Effect	Restores Motor Function	~	
	Improves Cognitive Function	J	

GT-02287 restores GCase function and demonstrates effect on entire disease cascade

GT-02287 has potential to be true disease-modifying therapy for Parkinson's and other CNS diseases



© 2024 - GAIN THERAPEUTICS Corporate Presentation Page 13

Single Ascending Dose

- Completed in March 40 subjects treated
- Generally well tolerated, no SAEs
- Exposures in humans reached levels observed in preclinical efficacy studies

Multiple Ascending Dose

- Completed in July 32 subjects
- Generally well tolerated, no SAEs
- Achieved therapeutic plasma levels with oral dosing



Upcoming Anticipated Milestones and Potential Value Inflection Points

2H 2024	 Start of Phase 1b POC clinical trial in GBA1-Parkinson's disease 3-month treatment, open label Safety and tolerability in patients Biomarkers of GCase disease cascade and PD disease 				
	 Type B FDA Meeting Potential target engagement readout (GCase Activity) 				
	 International Congress of Parkinson's Disease and Movements Disorders 				
	- September 27-October 1, Philadelphia				
	 Neuroscience 2024 				
	- October 5-9, Chicago				

1H 2025

- Potential clinical proof of concept based on biomarkers of GBA1-Parkinson's disease (interim data from Phase 1b clinical trial)
- Pre-IND Meeting with FDA in preparation of Phase 2 Clinical Trial






GT-02287

Differentiated Profile within Competitive Landscape

Clinical Stage Programs targeting GBA1 and GCase Disease Cascade

Competitive landscape is uncluttered





GT-02287 has Favorable Profile over other known MOAs and Modalities

Modality	GCase-Targeting Small Molecules	α-Syn-Targeting Small Molecules	α-Syn-Targeting Antibodies	Gene Therapy
Upstream Effect	✓			✓
Brain Penetration	✓	✓		
Convenience of Administration	✓	✓		(
Safety	✓	✓	✓	
Commercial (COGS/Pricing)	✓	✓	✓	



Page 18

GT-02287 has Best-in-Class Profile for GBA1-Parkinson's Disease of known GCasetargeting candidates

	Effect on Disease Cascade	GAIN THERAPEUTICS GT-02287	ि होता। BIA 28-6156	VANQUA BIO VQ-101
	Increases Lysosomal GCase Activity	✓		✓
	Reduces ER Stress	✓		
GCase	Reduces Toxic Lipid Substrates	✓	✓ ×	✓
Mechanism	Reduces Aggregated α-Synuclein	✓	S	✓
of Action	Improves Lysosomal Function	✓	✓	•
	Improves Mitochondrial Function	✓		
	Reduces Neuroinflammation	✓	•	
	Provides Neuroprotection	✓	•	
Disease-Modifying	Increases Dopamine Levels	✓		•
Effect	Restores Motor Function	✓		
	Improves Cognitive Function	✓		(





Large Pharma is interested in GBA1-related Programs

Recent acquisitions at >10x of Gain's market cap

	Effect on Disease Cascade	GAIN THERAPEUTICS GT-02287				
GCase Mechanism of Action	Increases Lysosomal GCase Activity	✓	\$1.2B+ in big pharma acquisitions of preclinical GBA programs in the last year			
	Reduces ER Stress	✓				
	Reduces Toxic Lipid Substrates	✓				
	Reduces Aggregated α-Synuclein	✓				
	Improves Lysosomal Function	~	Caraway Caraway MERCK \$610M in upfront/milestones			
	Improves Mitochondrial Function	✓	MITOKININ abbvie \$655M in upfront/milestones			
	Reduces Neuroinflammation	✓				
Disease- Modifying Effect	Provides Neuroprotection	v				
	Increases Dopamine Levels	✓	Gain is the only small molecule GBA approach to show disease modifying effects			
	Restores Motor Function	~				
	Improves Cognitive Function	~				



Large Market Potential for GT-02287 Across Several Neurodegenerative Diseases

Indication	Indication Rationale		Total Addressable Market (US)
GBA1-Parkinson's Disease	 Patients have dysfunctional GCase due to heterozygous GBA mutation 	150,000	\$1.5B
Idiopathic Parkinson's Disease	 GT-02287 has shown effects in preclinical WT models of PD 	1,000,000	\$10B
Gaucher Disease	 Patients dysfunctional GCase due to homozygous GBA mutation 	6,000	\$1.2B
Dementia with Lewy Bodies	 GT-02287 depletes aggregated alpha-synuclein which forms Lewy bodies 	1,000,000	\$10B
Alzheimer's Disease	 GT-02287 has shown positive effects in preclinical models of Alzheimer's disease 	5,800,000	\$58B



Company Background



CORPORATE BACKGROUND

- Established in 2017
- 28 employees in three locations:
 - HQ in Bethesda, Maryland
 - Lugano, Switzerland
 - Barcelona, Spain
- Founder and Executive Chairman:
 - Dr. Khalid Islam

INTELLECTUAL PROPERTY

Strong intellectual property estate

- Patent applications for 5 NCE families
- GT-02287 composition of matter patent application with term through 2038 (to be extended under Hatch Waxman Act)



FINANCIAL AND STOCK DATA

IPO (Nasdaq: GANX)

- March 2021
- Led by BTIG and Oppenheimer & Co.

CASH POSITION

- \$16.9 million at June 30, 2024

CAPITAL STRUCTURE

- 25.1 million shares outstanding
- No debt*

*Except a 9-year interest-free Swissgovernment loan ~\$0.5 million outstanding at September 30, 2023

ANALYST COVERAGE

BTIG: Tom Shrader, PhD, CFA: Buy

Oppenheimer & Co. Jay Olson, CFA: Outperform

H.C. Wainwright Ram Selvaraju, PhD: Buy

Chardan Keay Nakae, CFA: Buy

The Maxim Group Jason McCarthy, PhD: Buy



Company Contacts

Gene Mack: interim-CEO, CFO <u>gmack@gaintherapeutics.com</u>

Apaar Jammu: Manager, Investor Relations and Public Relations ajammu@gaintherapeutics.com